BeiCell Therapeutics
PrivateLast Round
Series B
Dec 26, 2025
Company Overview
BeiCell Therapeutics operates in Healthcare & Life Sciences and is based in Beijing. Its latest recorded funding round was a Series B round in December 2025.
BeiCell Therapeutics is a biotechnology company that develops off-the-shelf cell therapy products based on its proprietary chemically induced pluripotent stem cell (CiPSC) platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service, Usage-Based SaaS
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BeiCell Therapeutics Comparables
Compare BeiCell Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| BRL Medicine Inc. | 76% | |
| Base Therapeutics | 74% | |
| HebeCell | 72% |
For institutional investors. Book with your work email.
BeiCell Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 26, 2025 | ||||
| Series A | Dec 20, 2024 | ||||
| Pre Seed | Apr 18, 2024 | ||||
| Angel | Dec 20, 2022 |
For institutional investors. Book with your work email.
BeiCell Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 北京新毅控股集团有限公司 | Series A |
| BioTrack Capital | Angel, Pre Seed, Series A |
| Beijing Chang Development | Angel |
| 新毅投资 | Series A |
| ZhenFund | Angel, Pre Seed |
| 北京首都科技发展集团有限公司 | Series A |
| 燕缘创投 | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 5, 2026
Monthly visitors grew 54% MoM.
- Dec 20, 2024
Raised Series A with participation from BioTrack Capital and Green Pine Capital Partners.
For institutional investors. Book with your work email.
BeiCell Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BeiCell Therapeutics's valuation, stock price, and market status.
Is BeiCell Therapeutics a public or private company?
BeiCell Therapeutics is a private company.
What is the current stock price of BeiCell Therapeutics?
BeiCell Therapeutics is a private company, so its shares have no public market price. Caplight tracks BeiCell Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BeiCell Therapeutics worth (valuation)?
Valuation information for BeiCell Therapeutics is not publicly available.
Can I buy BeiCell Therapeutics stock?
BeiCell Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BeiCell Therapeutics's last funding round?
BeiCell Therapeutics's most recent funding round was Series B on December 26, 2025.
Who are the main investors in BeiCell Therapeutics?
Key investors in BeiCell Therapeutics include 北京新毅控股集团有限公司, BioTrack Capital, Beijing Chang Development, 新毅投资, ZhenFund.
Will BeiCell Therapeutics IPO soon?
No public IPO plans have been announced for BeiCell Therapeutics.
How can I track BeiCell Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in BeiCell Therapeutics's shares on secondary markets.